We love to hear from our listeners. Send us a message. On this week&#x27;s episode of the Business of Biotech, Aris Baras, M.D., SVP, Head of Regeneron Genetics Center (RGC) and Co-Head of Regeneron Genetic Medicines, talks about using large-scale human genetics to find better drug targets based on &quot;superhuman&quot; variants. Aris explains how multi-omics, linked health records, and AI are helping developers move faster in the clinic and reduce the odds of failure, while also pushing biotech toward earlier disease prediction and more preventive care. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Using Genetics To Discover New Treatments With Regeneron Genetics Center's Aris Baras, M.D. 

Business Of Biotech

Welcome back to the Business Of Biotech. I'm your host, Ben Comer, Chief Editor at Life Science Leader. And today I'm speaking with Aris Baras, M.D., Senior Vice President, Head of Regeneron Genetics Center and Co-Head of Regeneron Genetic Medicines.

Aris joined Regeneron in 2011 and helped found the Regeneron Genetics Center, or RGC, in 2013. The RGC database now contains over 3 million sequenced exomes through collaborations with more than 150 global partners. Research at the RGC has produced over 50 new genetic discoveries and has moved more than a dozen programs into the clinic.

Last April, Regeneron received FDA approval for Otar Mini, the first gene therapy approved to target the genetic cause of an ultra-rare type of hearing loss, a treatment capable of actually restoring natural hearing ability in patients. Qualifying patients in the U.S. can receive the treatment for free, which is amazing. I'll ask Aris for a little bit of background on that gene therapy and how it came together.

We'll talk about the work RGC is doing in genetic sequencing, RGC's global partnerships, and how it all translates into new therapies. Aris, thank you so much for being here. Thank you, Ben. Pleasure is all mine. Love your podcast, and I'm thrilled to be doing this with you. Thanks so much. Well, thank you. Thank you so much. I wanted to start off with your background.

You got several degrees from Duke University, a BS, an MBA, and an MD, and also, I believe, consulted for Liquidia Technologies during that time. Is that right? That's correct. You know, I was young. I didn't know what I wanted to do. I was trying to figure it out. Yeah, of course.

Using Genetics To Discover New Treatments With Regeneron Genetics Center's Aris Baras, M.D.

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Using Genetics To Discover New Treatments With Regeneron Genetics Center's Aris Baras, M.D.

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.